Company TRACON Pharmaceuticals, Inc.

TCON

US89237H3084

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 11:15:30 2024-04-26 am EDT			5-day change	1st Jan Change
1.78 ^USD	-0.56%		-11.73%	-50.60%

Apr. 03	TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned	CI
Mar. 06	HC Wainwright Adjusts Price Target on TRACON Pharmaceuticals to $6 From $7, Keeps Buy Rating	MT

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Companyâs clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.

Number of employees: 17

USD in Million	2022	Weight	2023	Weight	Delta
Therapeutics 100.0 %	0	nan %	12	100.0 %	-

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	nan %	12	100.0 %	-

Managers	Title	Age	Since
Charles Theuer CEO	Chief Executive Officer	60	06-06-30
Scott Brown DFI	Director of Finance/CFO	43	15-07-31
James L. Freddo CTO	Chief Tech/Sci/R&D Officer	69	20-04-30
Brenda Marczi LAW	General Counsel	-	21-07-19

Members of the board	Title	Age	Since
Martin Mattingly BRD	Director/Board Member	66	14-12-25
Saundra Pelletier BRD	Director/Board Member	54	20-03-18
Stephen Worland BRD	Director/Board Member	66	15-02-24
Rainer Twiford BRD	Director/Board Member	71	08-08-31
William LaRue BRD	Director/Board Member	73	14-06-30
Charles Theuer CEO	Chief Executive Officer	60	06-06-30
Carol Lam BRD	Director/Board Member	64	21-10-11
Lisa Johnson-Pratt BRD	Director/Board Member	60	21-03-01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,275,226	2,216,192 ( 97.41 %)	0	97.41 %

Name	Equities	%	Valuation
Ikarian Capital LLC 6.077 %	2,765,530	6.077 %	1 M $
Ikarian Capital LLC 5.870 %	2,670,930	5.870 %	1 M $
Lincoln Park Capital LLC 5.130 %	2,334,423	5.130 %	1 M $
Wayne Aaronson 1.576 %	716,925	1.576 %	308 278 $
Acadian Asset Management LLC 0.9096 %	413,909	0.9096 %	177 981 $
Squarepoint OPS LLC 0.9060 %	412,271	0.9060 %	177 277 $
Charles Theuer 0.8931 %	406,417	0.8931 %	174 759 $
Vanguard Group, Inc. (Subfiler) 0.5775 %	262,772	0.5775 %	112 992 $
BlackRock Institutional Trust Co. NA 0.5741 %	261,262	0.5741 %	112 343 $
Boothbay Fund Management LLC 0.5688 %	258,844	0.5688 %	111 303 $

TRACON Pharmaceuticals, Inc.

4350 La Jolla Village Drive Suite 800

92122-1243, San Diego

http://www.traconpharma.com

address TRACON Pharmaceuticals, Inc.(TCON)

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.79 USD

Average target price

37.5 USD

Spread / Average Target

+1,994.97%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals

	1st Jan change	Capi.
TRACON PHARMACEUTICALS, INC.	-50.60%	4.07M
CSL LIMITED	-4.66%	87.53B
SAMSUNG BIOLOGICS CO.,LTD.	+2.63%	40.42B
BIOGEN INC.	-20.44%	29.48B
UCB	+58.11%	25.43B
INCYTE CORPORATION	-17.92%	11.49B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.02%	11.3B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.61%	11.1B
SWEDISH ORPHAN BIOVITRUM AB	+4.64%	8.75B
INNOVENT BIOLOGICS, INC.	-8.42%	7.99B

Biopharmaceuticals